Astrana Health (NASDAQ:ASTH - Get Free Report) was downgraded by investment analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a note issued to investors on Tuesday, Zacks reports.
A number of other analysts have also commented on ASTH. Weiss Ratings reissued a "hold (c)" rating on shares of Astrana Health in a research report on Thursday, August 27th. Truist Financial raised their target price on shares of Astrana Health from $47.00 to $55.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Oppenheimer started coverage on shares of Astrana Health in a research note on Tuesday, September 15th. They issued an "outperform" rating and a $53.00 price target on the stock. Wall Street Zen cut shares of Astrana Health from a "buy" rating to a "hold" rating in a research report on Sunday, August 16th. Finally, Needham & Company LLC increased their price objective on shares of Astrana Health from $41.00 to $45.00 and gave the stock a "buy" rating in a research note on Friday, November 6th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Astrana Health presently has an average rating of "Moderate Buy" and a consensus price target of $50.38.
View Our Latest Analysis on ASTH
Astrana Health Stock Performance
Shares of Astrana Health stock opened at $29.65 on Tuesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.25 and a quick ratio of 1.25. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of 16.49 and a beta of 1.18. The stock's 50-day moving average is $36.01 and its 200-day moving average is $34.32. Astrana Health has a one year low of $18.08 and a one year high of $51.60.
Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.25. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. Astrana Health had a return on equity of 11.57% and a net margin of 1.36%. Astrana Health's revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.01 EPS. Equities analysts predict that Astrana Health will post 1.22 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Astrana Health
A number of institutional investors have recently added to or reduced their stakes in the company. Corient Private Wealth LP grew its holdings in Astrana Health by 1.6% during the second quarter. Corient Private Wealth LP now owns 24,905 shares of the company's stock worth $1,156,000 after purchasing an additional 399 shares during the period. Farther Finance Advisors LLC raised its stake in Astrana Health by 730.1% in the third quarter. Farther Finance Advisors LLC now owns 689 shares of the company's stock valued at $25,000 after buying an additional 606 shares during the period. Public Employees Retirement System of Ohio bought a new stake in Astrana Health in the second quarter valued at approximately $51,000. Sterling Capital Management LLC lifted its position in shares of Astrana Health by 17.2% in the third quarter. Sterling Capital Management LLC now owns 9,269 shares of the company's stock valued at $330,000 after buying an additional 1,359 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in shares of Astrana Health by 19.3% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 13,600 shares of the company's stock valued at $484,000 after buying an additional 2,200 shares during the last quarter. 52.77% of the stock is currently owned by institutional investors and hedge funds.
Astrana Health Company Profile
(
Get Free Report)
Astrana Health, Inc. is a physician-centric healthcare company that coordinates and delivers care through a network of primary care physicians, specialists and other providers. Its services include primary and specialty care, care coordination, hospital-based care and technology-enabled population health management. The company works with health plans and provider groups under value-based care arrangements, which emphasize coordinating care and managing patients' health needs across different settings.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.